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AKT activation controls cell survival in response to
HDAC6 inhibition
M Kaliszczak1, S Trousil1, T Ali1 and EO Aboagye*,1
HDAC6 is emerging as an important therapeutic target for cancer. We investigated mechanisms responsible for survival of tumor
cells treated with a HDAC6 inhibitor. Expression of the 20 000 genes examined did not change following HDAC6 treatment in vivo.
We found that HDAC6 inhibition led to an increase of AKT activation (P-AKT) in vitro, and genetic knockdown of HDAC6
phenocopied drug-induced AKT activation. The activation of AKT was not observed in PTEN null cells; otherwise, PTEN/PIK3CA
expression per se did not predict HDAC6 inhibitor sensitivity. Interestingly, HDAC6 inhibitor treatment led to inactivating
phosphorylation of PTEN (P-PTEN Ser380), which likely led to the increased P-AKT in cells that express PTEN. Synergy was
observed with phosphatidylinositol 3’-kinases (PI3K) inhibitor treatment in vitro, accompanied by increased caspase 3/7 activity.
Furthermore, combination of HDAC6 inhibitor with a PI3K inhibitor caused substantial tumor growth inhibition in vivo compared
with either treatment alone, also detectable by Ki-67 immunostaining and 18F-FLT positron emission tomography (PET). In
aggregate AKT activation appears to be a key survival mechanism for HDAC6 inhibitor treatment. Our findings indicate that dual
inhibition of HDAC6 and P-AKT may be necessary to substantially inhibit growth of solid tumors.
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The acetylation status of protein lysines including that of
histones is regulated by the reversible post-translational
modification activities of histone deacetylases (HDACs; more
accurately, lysine deacetylates) and histone acetyltrans-
ferases. Because these proteins are deregulated in cancer,
there is a strong interest to inhibit their function. HDACs fall
into four classes consisting of 18 genes,1 including zinc-
dependent class I (HDACs 1, 2, 3 and 8), II (HDACs 4, 5, 6, 7, 9
and 10) and IV (HDAC 11) enzymes, and nicotinamide
adenine dinucleotide-dependent class III enzymes (sirtuins).
Althoughmost clinically relevant HDAC inhibitors developed to
date represent drugs that modify chromatin – the prototype
epigenetic therapy – compounds that target the class IIb
HDAC, HDAC6 are distinguished by their ability to deacetylate
non-histone substrates. HDAC6 inhibition has recently
emerged as an attractive target for the treatment of cancer.
HDAC6 was shown to deacetylase a diverse set of substrates
involved in tumorigenesis including HSP90, α-tubulin, cortac-
tin and peroxiredoxins, but, importantly, unlike other histone
deacetylases, selective inhibition of HDAC6 is believed not be
associated with severe toxicity and HDAC6 knockout does
not lead to embryonic lethality.2–6 The role of HDAC6 in the
misfolded/damaged proteins response, particularly important
for tumor cells that produce large amounts of these aberrant
proteins has also been exploited.7 A HDAC inhibitor with
enhanced selectivity for HDAC6, ACY-1215, is currently being
tested in phase I/II against refractory multiple myeloma in
combination with proteasome inhibitor bortezomib (clinical
trial NCT 01323751). HDAC6 inhibitors have been less studied
in the context of solid tumors.
Phosphatidylinositol 3’-kinases (PI3K) are lipid kinases
that catalyze production of phosphatidylinositol 3,4,5-tripho-
sphate, which in turn functions to recruit and activate several
cognate targets including AKT. PI3K activation gain of function
can occur through amplification or mutation ofPIK3CA located
on chromosome 3q26.3 that encodes PI3K p110α. Loss of
function can occur through mutation of PTEN, a tumor
suppressor gene on chromosome 10q23, which encodes a
dual-specificity lipid and protein phosphatase that negatively
regulates AKT. Co-existence of both mutations has also been
reported in endometrial cancer.8 PTEN inactivation leads to
AKT phosphorylation and consequently activation of multiple
downstream substrates including the mTOR proteins, cas-
pases, cell cycle proteins and NF-κB to promote cell survival,
metastasis and chemoresistance.9,10 Activation of the PI3
kinase-AKT pathway represents one of themajor mechanisms
employed by cancer cells for cell survival, and by extension the
pathway is often deregulated in cancer cells that are refractory
to chemotherapy. For example DNA-PK-dependent AKT
activation is implicated in acquired platinum-resistant ovarian
cancer cells,11 whereas PTEN-dependent AKT activation is
associated with resistance to small molecule EGFR kinase
inhibitors in lung cancer.12
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We previously described a novel HDAC6 selective inhibitor,
C1A, that showed antitumor activity in a solid tumor model of
human colorectal cancer.13 The molecular mechanisms by
which tumors survive HDAC6 inhibitor treatment, however,
remain unresolved. Here we investigated potential survival
mechanism using C1A as a model HDAC6 inhibitor active
in solid tumors. Our results reveal a previously unknown
mechanism by which AKT activation regulates survival
following HDAC6 inhibitor treatment.
Results
Mechanisms underlying loss of growth response during
HDAC6 inhibition. To understand potential drug resistance
genetic mechanisms, we performed a gene array analysis
on tumor samples (HCT-116 colon cancer xenografts: a
subcutaneously growing tumor derived from injecting the
HCT-116 cell line into mice) obtained from mice treated daily
with C1A for 14 days – a time point when recovery from drug
inhibition was seen.13 In total, 20000 genes were tested
(GEO accession number: GSE64662; http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE64662). A representa-
tive set of the genes is shown in Table 1. After adjustment for
multiple testing using Benjamini–Hochberg, none of the
genes was significantly expressed between the control and
treated groups at either the qo0.05 or qo0.1 levels.
Furthermore, no obvious genotypes linked to a classical
resistance mechanism (e.g., de-regulation of the ABC
transporters) were found. Furthermore, C1A was found to
be a weak substrate of the ABC transporters, ABCG2, P-gp
and MRP1 (Supplementary Figure S1).
AKT represents one of the most important proteins that is
adaptively regulated in relation to cancer cell survival, and
increased phospho-AKT (P-AKT) is thought to contribute to an
apoptotic resistance phenotype.14–16 HDAC6 inhibition by
C1A (increased acetyl α-tubulin with no change in acetyl H3)
was found to be associated with a time-dependent increase of
P-AKT (Figure 1a). Genetic knockdown of HDAC6 in HCT-116
or mouse embryonic fibroblast (MEF) cells phenocopied
treatment with C1A in relation to P-AKT accumulation
(Figures 1b and c). Treatment-induced increased P-AKT also
occurred in a panel of cancer lines from different origins and
PTEN mutation status8,17 (Figure 1d). For each set of cell
lines, HCT-116 cell lysates (heterozygous for PIK3CA,
c.3140A4G, and homozygous for PTEN, c.68_69insG) were
used to permit optimal display of protein expression.
Increased P-AKT was seen in both PTEN mutant and wild-
type cell lines inferring that mutation status per se did not
explain the increased P-AKT. HEC1B cells that are wildtype for
PTEN but harbor mutant PIK3CA and KRAS8 also showed
increased P-AKTactivity. PTEN protein loss can occur through
promoter methylation, loss of heterozygosity and regulation at
the RNA or protein level making examination of mutational
status alone insufficient to predict protein function. P-AKT
expression levels were very high in two cell lines (MDA-
MB-468 and Ishikawa) that are null for PTEN protein,8,17
relative to that in HCT-116 cells, and importantly showed
no change following C1A treatment (Figure 1d), suggesting
that PTEN protein may have a role in the activation of AKT
following treatment with a HDAC6 inhibitor. To rule out the
notion that PTEN expression per se may predict cell line
sensitivity to C1A, we evaluated the association betweenC1A-
dependent growth inhibition of the NCI60 cell line panel and
expression of PTEN mRNA, and observed no linear associa-
tion between growth and PTEN expression levels (Figure 2a).
In isogenic HCT-116 and HCT-116 PTEN null cells, cell
survival following HDAC6 inhibitor treatment with C1A or
tubastatin A was marginally higher in the PTEN null cells
(Figure 2b); in contrast PTEN null cells were substantially
more resistant to treatment with MS-275 (Class I HDAC
inhibitor) or SAHA (a pan HDAC inhibitor), indicating differ-
ences in drug–response profile.18
We wondered if PTEN activity rather than expression may
be responsible for the HDAC6 inhibitor-induced AKT activa-
tion. We investigated phosphorylation of the PTEN C-terminal
serine–threonine cluster.19,20 Treatment with C1A increased
phospho-PTEN (P-PTEN Ser380) expression at 30–60 min
(Figure 2c). A higher molecular weight band was observed
at 120 min, possibly owing to additional post-translational
modifications of PTEN, similar to that observed with Okadaic
acid (Figure 2c). We postulated that C1A treatment decreases
PTEN lipid phosphatase activity via phosphorylation and
consequently activates P-AKT (P-AKT-Th308; Figure 2c). We
further investigated whether C1A treatment also activated
AKT downstream substrates: hypoxia-inducible factor-1 α and
glucose trasporter-1 (GLUT1).21 Both HIF1-α and GLUT1
protein expression increased upon 4 h of C1A treatment at 5 or
10 μM (Figure 3a). Uptake of 18F-fluorodeoxyglucose ([18F]
FDG) also increased with C1A treatment at 10 μM C1A by
twofold in keeping with the higher GLUT1 protein expression
(Figure 3b). This demonstrates functional significance of the
drug-induced increased P-AKT.
Combination therapy with AKT pathway inhibitors. Using
caspase 3/7 activity as a surrogate for apoptotic cell death
induction, we showed that C1A treatment-induced apoptosis
in both HCT-116 human colon and MDA-MB-231 human
breast cell lines by 3.7- and 3.5-fold, respectively, but not
in CDC-18Co normal colon fibroblast cell line (Figure 4a). To
gain some insight into the molecular mechanisms, we
examined the effect of the transcription inhibitor actinomycin D
and the translation inhibitor cycloheximide. Both actinomycin D
and cycloheximide abrogated caspase 3/7 activation induced
by C1A (Figure 4b). These data suggest that de novo
synthesis of pro-apoptotic factors or repression of anti-
apoptotic factors accompanies apoptosis induced by C1A
treatment. While we did not investigate the specific factors
involved, two pro-apoptotic genes – BAX and XAF1 – were
previously reported by us to be upregulated in vivo following
C1A treatment.13 Surprisingly, neither actinomycin D nor
cycloheximide prevented the HDAC6 inhibitor-induced
increase of P-AKT by C1A (Figure 4c), suggesting that
the two process resulting from C1A treatment – apoptosis
induction and AKT activation – are mechanistically distinct.
From the foregoing, we rationalized that a therapeutic
combination strategy would involve HDAC6 inhibition together
with inhibition of AKT phosphorylation. Simultaneous expo-
sure of HCT-116 cells to C1A and API-2 (pan-AKT inhibitor) or
BEZ235 (dual PI3K/mTOR inhibitor) retarded the C1A
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induction of P-AKTexpression (Figure 4d). Increased caspase
3/7 activity was observed when BEZ235 was combined with
HDAC6 inhibitors C1A or tubastatin A (Figure 4e). To provide a
genetic basis for the above findings, we further treated
HCT-116 or isogenic AKT1/2 knockout cells with C1A.
Caspase 3/7 activity was higher in the latter cell line
(Figure 4f).22 Regarding efficacy, synergy was seen when
HDAC6 inhibitor treatment was combined with a variety of
PI3K/AKT/mTOR inhibitors including rapamycin, wortmanin,
LY29004, BEZ235 and API-2 (Supplementary Table S1).
To verify whether AKT inhibition potentiated the efficacy of a
HDAC6 inhibitor in vivo, HCT-116 tumor-bearing mice were
treated with C1A in combination with BEZ235. C1A treatment
alone was associated with a Tumor Growth Delay (TGD2x) of
3.8± 1.3 days and a Total Growth Inhibition (TGI) of 69%
(Figure 5a). Combination treatment (given 6 h apart) was
associated with a TGD2x of 8.2±1.3 days and a TGI of 74%,
and the effect was more pronounced when drugs were given
30 min apart (TGI of 115%; TGD2x cannot be calculated in this
case). No toxicity as measured by body weight loss was
observed (Figure 5b).
These data indicate that, when combined appropriately, a
drug that inhibits P-AKT can positivily modulate the activity
of a HDAC6 inhibitor as demonstrated with C1A. P-AKT
expression was low at 30 min following injection of BEZ235
(Figure 5c). Comparatively, single treatment of C1A showed
higher P-AKTexpression that was retarded by the combination
regimen at 6 h. Efficacy of the combination treatment in tumors
could be predicted by immunostaining the proliferative
biomarker Ki-67 in excised tumors obtained at 48 h or by
non-invasive imaging with the proliferation marker [18F]
fluorothymidine ([18F]FLT)-PET23 at 48 h (Figures 5d and e).
Discussion
HDAC6 is emerging as an important therapeutic target for
cancer. We investigated mechanisms responsible for survival
of tumor cells treated with a HDAC6 inhibitor and report that
HDAC6 inhibition promotes inactivating PTEN phosphoryla-
tion and consequently activation of AKT. In the development
of new drugs, it is important to ascertain mechanisms of
resistance so as to optimize treatment outcome. Previous
studies documented that the HDAC6 inhibitor C1A induced
Table 1 Differential gene expression analysis of HCT-116 tumors following 14 days of treatment with C1A at 40 mg/kg/day compared with vehicle-treated tumors (n= 3
per group)
Gene symbol logFC P-value Adjusted
P-value
Gene title
NTHL1 − 0.736677656 2.55E-05 0.777442325 Nth endonuclease III-like 1 (E. coli)
ALCAM − 0.920675312 0.000112974 0.777442325 Activated leukocyte cell adhesion molecule
ZNF655 0.766978363 0.000116352 0.777442325 Zinc finger protein 655
URB2 0.865943736 0.000119016 0.777442325 URB2 ribosome biogenesis 2 homolog (S. cerevisiae)
NR3C1 − 0.799750027 0.000119338 0.777442325 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid
receptor)
FLYWCH1 0.679778646 0.000179763 0.777442325 FLYWCH-type zinc finger 1
CSGALNACT1 − 0.882311251 0.000199763 0.777442325 Chondroitin sulfate N-acetylgalactosaminyltransferase 1
PPT2 0.711507486 0.000227027 0.777442325 Palmitoyl-protein thioesterase 2
ALDH1B1 0.753485489 0.000240906 0.777442325 Aldehyde dehydrogenase 1 family, member B1
ALDH8A1 0.712958175 0.000293548 0.777442325 Aldehyde dehydrogenase 8 family, member A1
RPS27A 0.686609012 0.000311095 0.777442325 Ribosomal protein S27a
C6orf57 − 0.579207261 0.000320163 0.777442325 Chromosome 6 open reading frame 57
SAMD5 0.736334559 0.000337219 0.777442325 Sterile alpha motif domain-containing 5
ALDH1B1 0.678048588 0.00033818 0.777442325 Aldehyde dehydrogenase 1 family, member B1
MYBBP1A 0.563704418 0.000340876 0.777442325 MYB binding protein (P160) 1a
KLK3 − 0.606943925 0.000422135 0.777442325 Kallikrein-related peptidase 3
GFOD1 0.617851796 0.000447255 0.777442325 Glucose-fructose oxidoreductase domain-containing 1
SMUG1 0.583214452 0.000477869 0.777442325 Single-strand-selective monofunctional uracil-DNA glycosylase 1
SAPS2 0.871468969 0.00048278 0.777442325 SAPS domain family, member 2
SEMA3C − 0.924371191 0.000506638 0.777442325 Sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3C
TMCC3 − 0.600920858 0.000523683 0.777442325 Transmembrane and coiled-coil domain family 3
B4GALT2 0.513925699 0.000532725 0.777442325 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2
CPEB1 − 0.556732661 0.000571699 0.777442325 Cytoplasmic polyadenylation element binding protein 1
AKR1C3 − 0.649604098 0.000591514 0.777442325 Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid
dehydrogenase, type II)
ITGB8 − 0.847908487 0.000593268 0.777442325 Integrin, beta 8
LOC441155/
ZC3H11 A
− 0.710048175 0.000617314 0.777442325 Zinc finger CCCH-type domain-containing pseudogene/zinc finger
CCCH-type containing 11A
BDH1 0.57030334 0.000617955 0.777442325 3-hydroxybutyrate dehydrogenase, type 1
SLC43A3 0.674730913 0.000653629 0.777442325 Solute carrier family 43, member 3
RUNX1 − 0.623212555 0.000703953 0.777442325 Runt-related transcription factor-1
EIF4A1 0.527807794 0.000712078 0.777442325 Eukaryotic translation initiation factor 4A1
FOXD4/FOXD4L1 0.574366602 0.000724742 0.777442325 Forkhead box D4/forkhead box D4-like 1
SERPINF1 − 0.873740093 0.000726528 0.777442325 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment
epithelium derived factor), member 1
SCAMP5 0.491463362 0.000734319 0.777442325 Secretory carrier membrane protein 5
PAK6 0.584001518 0.000749791 0.777442325 p21 protein (Cdc42/Rac)-activated kinase 6
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Figure 1 HDAC6 inhibition induces AKT phosphorylation. (a) P-AKT levels following treatment with C1A at 10 μM for the indicated time in HCT-116 cells. Corresponding data
from same lysates for acetyl α-tubulin, α-tubulin, acetyl histone H3 (acetyl H3), H3, total AKT (AKT) and β-actin (actin) are shown. Densitometry data are expressed as fold
increase over control (P-AKT is normalized to AKT). (b) Impact of genetic knockdown of HDAC1 and HDAC6 by siRNA on their respective substrates, acetyl H3 and acetyl
α-tubulin, and on P-AKT levels in HCT-116 cells. (c) P-AKTexpression in Mouse Embryonic Fibroblasts (MEF) HDAC6 WTand HDAC6− /−, relative to expression of HDAC6 and
acetyl α-tubulin. (d) Effect of HDAC6 inhibition by C1A on P-AKT levels in a panel of cancer cell lines. Cells were treated with 10 μM of C1A for 8 h and subject to western blotting.
Densitometry data are expressed as fold increase over control (P-AKT is normalized to AKT). Mutation status of PTEN is indicated: mutant (Mut) or wildtype (WT). The human cell
lines used and their background include: HCT-116 (colon carcinoma; primary), MDA-MB-361 (breast adenocarcinoma; brain metastasis), MDA-MB-468 (breast adenocarcinoma;
plural effusion metastasis), A431 (skin carcinoma; primary), DU-145 (prostate carcinoma; brain metastasis), BX-PC3 (pancreatic adenocarcinoma; primary), Ishikawa
(endometrial adenocarcinoma; primary), Kelly (neuroblastoma; brain), SH-SY5Y (neuroblastoma and subline of parental line SK-N-SH; bone marrow metastasis), SKNAS
(neuroblastoma; bone marrow), T47D (breast adenocarcinoma; plural effusion metastasis), A2780 (ovarian carcinoma; primary), SKOV-3 (ovarian adenocarcinoma; ascites),
A549 (lung adenocarcinomic; primary), HEC1B (endometrial adenocarcinoma; primary), HepG2 (hepatocellular carcinoma; primary) and LNCaP (prostate carcinoma;
supraclavicular lymph node metastasis)
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apoptosis in cell lines derived from solid tumors, however,
tumor growth survival occurred in spite of continued drug
treatment in mice.13 Our studies subsequently unraveled a
mechanism of resistance involving inactivating PTEN
phosphorylation.24
Other than gene expression, the lipid phosphatase activity
and protein stability of PTEN can be regulated through
acetylation, phosphorylation or ubiquitination.25 HDAC6 inhi-
bition was recently reported to induce PTEN acetylation and
activity;26 however, we found no differences in acetylated-
lysine of PTEN bymass spectrometry following C1A treatment
of HCT-116 cells (data not shown). We also considered
activation of PIK5-L1 gene that is enhanced at an early time
point (24 h) following C1A treatment as a potential reason for
increased P-AKT,13,27 however, we ruled out this possibility
Figure 2 HDAC6 inhibition in relation to PTEN expression and activation. (a) Relationship between the growth inhibitory effect of C1A and mRNA levels of PTEN. The growth
inhibitory effect of C1Awas tested across the NCI60 panel following 72 h exposure. Data on mRNA levels and PIK3CAmutation status were from the Developmental Therapeutics
Program (NCI/NIH) available online. (b) Growth inhibitory effect of HDAC inhibitors in HCT-116 cells proficient (NEO) and deficient (#35) in PTEN.18 HCT-116 Neo and #35 were
treated with HDAC6 inhibitors (C1A and Tubastatin A), pan HDAC inhibitor (SAHA) and HDAC class I-specific inhibitor (MS-275) for 24 h. All compounds were used at 10 μM.
(c) Impact of C1A treatment on PTEN phosphorylation. P-PTEN (Ser380) expression was compared to total PTEN, P-AKT (Thr308) and total AKTexpression. Densitometry data
are the ratios between P-PTEN and PTEN and normalized to untreated control. For clarity, two exposure times for western blot were used
Figure 3 HDAC6 inhibition induces HIF1α-mediated response, Glut1 expression
and glucose uptake. (a) HCT-116 cells were treated with C1A at 5 μM and 10 μM for
4 h and subject to western blotting. Densitometry data were normalized to tubulin
levels. (b) [18F]FDG uptake in HCT-116 cells following treatment with C1A at 5 and
10 μM for 4 h (expressed as a % of the injected dose per mg of cellular protein).
*P= 0.036, ***Po0.0001
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given the persistence of P-AKT increase when transcription or
translation was blocked. PTEN is also subject to phosphoryla-
tion at the C-terminal serine–threonine cluster (Ser370,
Ser380, Thr382, Thr383 and Ser385) that affects its phos-
phatase activity by restricting the protein to the cytoplasm and
away from the plasma membrane where it antagonizes PI3K/
AKT signaling.19,20 Treatment with C1A increased phospho-
PTEN (P-PTEN Ser380) expression at 30–60 min. The higher
molecular weight band observed at 120 min is possibly due to
additional post-translational modifications of PTEN, similar to
that observed with Okadaic acid in our study and that of
others.24 We postulate that C1A treatment decreases PTEN
lipid phosphatase activity via phosphorylation and conse-
quently activates PI3K-AKT.
Two opposing processes – caspase 3/7 activation and
AKT-dependent survival – occurred as a consequence of
HDAC6 inhibition. We report that the mechanisms are distinct;
cell death was dependent on transcription and translation,
whereas AKT activation was not. Treatment of tumor cells or
xenografts with PI3K/AKT/mTOR pathway inhibitors abro-
gated the increased P-AKT expression and enhanced
antitumor activity of C1A at well-tolerated doses. The effect
was schedule dependent. It could be argued that inhibition of
the PI3K/AKT/mTOR axis will also allow HDAC6 inhibition to
be more effective in cells that already harbor inactivating
mutations or deletions of PTEN (hence, constitutive P-AKT),
even though these cells do not respond to HDAC6 inhibition
by activating P-AKT.
Regarding mechanistic biomarkers of efficacy, the combi-
nation of C1A and BEZ235 could be monitored with [18F]FLT-
PET in HCT-116 tumor-bearing mice as early as 48 h.
Interestingly, our result also indicate that, following activation
of AKT pathway and GLUT1 expression, HCT-116 cells
upregulate glucose uptake, demonstrated as an increase of
[18F]FDG-PET uptake at 4 h after treatment. PET imaging
could therefore be used in the pre-clinical and clinical settings
to monitor both anti-proliferative and survival mechanism
following treatment with HDAC6 inhibitors.
In conclusion, inactivating PTEN phosphorylation and AKT
activation appear to be key survival mechanisms for HDAC6
inhibitor treatment of solid tumors. Our findings indicate that
dual inhibition of HDAC6 and P-AKT may be necessary to
substantially inhibit growth of solid tumors.
Materials and Methods
Compounds. C1A was synthesized in house,13 SAHA and tubastatin A were
purchased from Cayman Chemical (Ann Arbor, MI, USA). API-2 was from obtained
from Tocris (Abingdon, UK). BEZ235 was from LC Laboratories (Woburn, MA,
USA). Cycloheximide, actinomycin D and LY29004 were from Calbiochem (San
Diego, CA, USA). Okadaic acid was purchased from Cell Signalling (Danvers, MA,
USA). Fumitremorgin C, MK-571, vinblastine, rapamycin, wortmanin and LY29004
were from Sigma (St. Louis, MO, USA).
Antibodies. Antibodies against P-AKT (Ser473, catalog 9271), P-AKT (Thr308,
catalog 9275) and AKT (catalog 9272), HDAC1 (catalog 5356), HDAC6 (catalog
7558), P-PTEN (Ser380, catalog 9551) and PTEN (catalog 9188), α-tubulin (catalog
2144), acetyl α-tubulin (catalog 5335), Histone H3 (catalog 9715), P-DNA-PK
(Ser2056, catalog 4215), acetyl lysine (catalog 9441) and HIF1-α (catalog 3716)
were from Cell Signalling. Antibody against acetyl histone H3 (catalog 06-599) was
from Millipore (Nottingham, UK). Glut1 (catalog ab40084) and β-actin (catalog
ab6276) antibodies were from Abcam (Cambridge, UK). Secondary goat anti-mouse
Figure 4 HDAC6 inhibition induces caspase 3/7 activation that is potentiated by PI3K/AKT inhibition. (a) Caspase 3/7 activity following 24 h treatment with vehicle (control)
or C1A at 5 μM in HCT-116, MDA-MB-231 and CCD-18Co cells. Data were normalized to protein content (***Po0.0001). (b) Impact of transcription inhibitor actinomycin D
(AD – 10 μg/ml) and protein synthesis inhibitor cycloheximide (CHX – 5 μg/ml) on caspase 3/7 activity following treatment with HDAC6 inhibitors (24 h treatment) (***Po0.0001).
(c) Impact of actinomycin D and cycloheximide as above on P-AKT and total AKT expression. (d and e) Effect of API-2 and BEZ235 on AKTactivation mediated by C1A. The
compounds were co-incubated for 24 h at the indicated concentrations. (f) Effect BEZ235 (100 nM) on caspase 3/7 activation mediated by C1A (10 μM) or tubastatin A (10 μM).
The compounds were co-incubated for 24 h as indicated **P= 0.0055, *P= 0.0205. (g) Effect of C1A on wild-type HCT-116 (WT) and HCT-116 cells with knockout of AKT1/2
(AKT1/2-). Cells were treated for 6 h at 40 μM, washed and left for further 18 h. **P= 0.0051
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(catalog sc-2005) and anti-rabbit (catalog sc-2004) HRP antibodies were from Santa
Cruz (Heidelberg, Germany).
Cells. HCT-116 cells were obtained from the American Type Cell Culture
Collection and authenticated by short tandem repeat profiling under contract by
DDC Medical (London, UK). Ishikawa was purchased from Sigma. MEFs proficient
(WT) and deficient (KO) in HDAC6 were kindly provided by Professor Tso-Pang Yao
(Duke University, USA); KELLY, SH-SY5Y and SKNAS by Dr Louis Chesler (Institute
of Cancer Research, UK), AKT1/AKT2 HCT-116-deficient cells from Professor Bert
Vogelstein (Johns Hopkins University, USA), PTEN knockout variants of HCT-116
cells were generously provided by Dr Todd Waldman (Georgetown University, USA).
3T3 and 3T3 transfected with c-DNA expressing P-gp (pHamdr1) were kindly
provided by Dr. E Schuetz from St. Jude’s Children Research Hospital (USA) and
MCF7 and mitoxantrone (MX)-resistant sub-clones MCF7-MX by Dr E Schneider
from the University of Maryland (USA). All other cell lines were obtained from ATCC.
All cells were passaged in our laboratory for fewer than 6 months on receipt and
were tested mycoplasma free.
Growth inhibitory assay. Drug concentrations that inhibited 50% of cell
growth (GI50) were determined using a sulforhodamine B (SRB) technique as
described elsewhere.28
Tumor xenografts. All animal experiments were done by licensed investiga-
tors in accordance with the United Kingdom Home Office Guidance on the
Operation of the Animal (Scientific Procedures) Act 1986 (HMSO, London,
UK, 1990) and within guidelines set out by the UK National Cancer Research
Institute Committee on Welfare of Animals in Cancer Research.29 HCT-116 (5 x 106)
cells were injected subcutaneously in 100 μl volumes into the flank of female
nu/nu-BALB/c mice (Harlan, Blackthorn, UK). Animals entered treatment groups
when tumors reached ~ 50 mm3. Animal weights and tumor volumes were
determined daily.
Gene array. Animals were treated for 14 days with C1A at 40 mg/kg/day (or
vehicle) and the tumors excised and snap frozen. Total RNA was extracted from
tumors using RNeasy mini Kit (Qiagen, Manchester, UK) and hybridized to
Affymetrix human genome U219 microarray (Affymetrix, Santa Clara, CA, USA).
Studies were performed under contract by AlphaMetrix biotech (Rödermark,
Germany). Raw data were normalized using robust multi-chip average in R.30
Differential gene expression analysis was conducted using the ‘limma’ package and
the adjusted P- value was derived by the Benjamini & Hochberg method.31
Immunoblotting. Cells and tumor tissue samples were prepared and subject
to western blotting as previously described.32 Densitometry ratios were determined
using Image J software (Rasband, W.S., Image J, US National Institutes of Health,
Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997-2015).
In vitro [18F]FDG-cell uptake. Cells were seeded on day 1 and on day 2,
fresh growth medium, containing ~ 0.74MBq [18F]FDG, was added to individual
wells. Cell uptake was measured following incubation at 37 °C in a humidified
atmosphere of 5% CO2 for 1 h. The plates were subsequently placed on ice,
Figure 5 AKT inhibition potentiates the activity of HDAC6 inhibitor treatment in vivo. (a) Nude mice bearing HCT-116 tumor xenograft were administered BEZ235 at 25 mg/kg
QD. (p.o.) or C1A at 20 mg/kg (QD) (i.p.) alone or in combination (30 min or 6 h apart). Relative tumor volumes± s.e.m. are shown. n= 8 per group. (b) Body weight
measurements following treatment as measure of systemic drug tolerability. (c) P-AKTexpression measured in HCT-116 tumors treated with BEZ235 (25 mg/kg), C1A (20 mg/kg)
or combination (no delay between injections) followed by excision of the tumor (at the indicated time post treatment) and analysis by western blotting. Densitometry data of P-AKT
were normalized to AKT and to vehicle-treated controls. (d) Representative images of Ki-67 immunostained tumor sections showing proliferative Ki-67 positive cells (brown).
Scale bars, 10 μm. (e) Summary of Ki-67 staining from 10 random pictures per slice (n= 2 slices per tumor per group); the positive cells were counted using Image J software.
The Ki-67 positive cells were expressed as a percentage of total cells counted. All error bars show s.e.m. (*** Po0.0001, two tailed student t-test). (f) [18F]FLTuptake following
treatment for 2 days with BEZ235 or/and in combination with C1A. Mice were treated with BEZ235 (at 25 mg/ kg QD) or with C1A (at 20 mg/kg QD) alone or in combination
(30 min apart) n= 3. The area under the curve represent the [18F]FLT uptake over 60 min
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washed with ice-cold PBS and lyzed in RIPA buffer. Cell lysates were transferred
into counting tubes and decay-corrected radioactivity was determined on a
gamma counter (Cobra II, Packard, PerkinElmer, Beaconsfield, UK). Data were
expressed as percentage of total radioactivity incorporated into cells, normalized for
total cellular protein.
Caspase 3/7 assay. Caspase 3/7 activity was determined using Promega's
caspase 3/7 assay according to the manufacturer's instructions. In brief, cells were
transferred to a white opaque 96-well plate, incubated for 1 h with Caspase-Glo
reagent and the enzymatic activity of caspase 3/7 was measured using a TopCount
counter and normalized with the protein content.
SiRNA knockdown. Transient knockdown of HDAC1, HDAC6 in HCT-116 cells
were performed using ON-TARGETplus SMARTpool siRNAs (Dharmacon,
Lafayette, CO, USA) with wet reverse transfection according to manufacturer’s
instructions. RNAiMAX (Invitrogen) was used as transfection reagent.
[18F]FLT tumor PET imaging. HCT-116 (5 × 106) cells were injected on the
back of female nu/nu-BALB/c athymic nude mice. When xenografts reached
~ 100 mm3, HCT-116 tumor-bearing mice were treated with C1A or BEZ235
alone or in combination. At 48 h post treatment, the animals were scanned on a
dedicated small animal PET scanner (Siemens Inveon PET module; Siemens,
Erlangen, Germany) following a bolus intravenous injection of 3.7 MBq of [18F]
fluorothymidine ([18F]FLT) and tumor uptake analyzed as previously described.32
Dynamic emission scans were acquired in list-mode format over 60 min. The
acquired data were then sorted into 0.5 mm sinogram bins and 19 time frames for
image reconstruction, which was done by filtered back projection. Cumulative
images of the data (30–60 min) were used for visualization of radiotracer
uptake and to define the regions of interest (ROIs) across several slices with the
Siemens Inveon Research Workplace software (3D ROIs were defined for each
tumor). The count densities were averaged for all ROIs at each of the 19 time
points to obtain a time versus radioactivity curve. The radiotracer uptake in
tumor regions was normalized to that of the heart of the same animal. The
normalized uptake value at 60 min post injection (NUV60) was used for
comparisons. The area under the NUV curve was calculated as the integral of
NUV from 0 to 60 min.
Ki-67 immunostaining. For histological evaluation of the degree of tumor
proliferation, tumors were excised after imaging, fixed in formalin, embedded in
paraffin and cut into 5.0 μm sections and subject to Ki-67 immunostaining and
analysis as previously described.32
Combination studies in vitro. HCT-116 cells were seeded on day 1 in a
volume of 100 μl and treated on day 2 with a range of concentration of C1A and
tubastatin A around the GI50 (0.1–40 μM) in a volume of 50 μl. Simultaneously,
different inhibitors were added at the indicated concentration in a volume of 50 μl.
The cells were incubated for an additional 72 h and the growth inhibitory effect was
evaluated using the SRB assay. The combination index was determined using the
CalcuSyn software version 2.1. CIo1 indicates synergistic effect; CI= 1, additive
effect; and CI41, no significant combination effect.
Permeability. Permeability of test compounds was performed using the
transwell assay as previously described.33
Statistical analysis. Two tailed student’s t-tests were performed using
GraphPad prism software, and P-values o0.05 using a 95% confidence interval
were considered significant. Data are reported as mean±S.E.M. of at least three
independent experiments unless otherwise stated. *Po0.05, **Po0.005,
***Po0.0001. NS, not significant.
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